

Vaccine Highlights

Recommendations, schedules, and more

Editor's note: The information in Vaccine Highlights is current as of May 10, 2013.

The next ACIP meetings

A committee of 15 national experts, the Advisory Committee on Immunization Practices (ACIP) advises CDC on the appropriate use of vaccines. ACIP meets three times a year in Atlanta; meetings are open to the public. The next two meetings will be held on June 19–20 and October 23–24. For more information, visit www.cdc.gov/vaccines/acip/index.html.

ACIP periodically issues public health recommendations on the use of vaccines. Clinicians who vaccinate should have a current set for reference. Published in the *Morbidity and Mortality Weekly Report (MMWR)*, ACIP recommendations are easily available. Here are sources:

- Download them from links on IAC's website: www.immunize.org/acip.
- Download them from CDC's website: www.cdc.gov/vaccines/pubs/acip-list.htm.

Immunization schedules

On Feb. 1, CDC published "Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and Adults Aged 19 Years and Older—United States, 2013." You will find IAC's reformatted version of the 2013 U.S. Immunization Schedule for Adults Age 19 Years and Older on pages 6–8 of this issue of *Vaccinate Adults*.

IAC has developed laminated, 6-page, full-size color versions of both 2013 immunization schedules, the child and teen, as well as the adult. They are available for purchase. For more information, visit www.immunize.org/shop/laminated-schedules.asp.

Meningococcal vaccine news

On March 22, CDC published ACIP recommenda-

tions titled *Prevention and Control of Meningococcal Disease*. The recommendations summarize previously published recommendations including those that call for (1) routine vaccination with a quadrivalent meningococcal conjugate vaccine (MCV4) for adolescents age 11 or 12 years, with a booster dose at age 16 and (2) routine vaccination for people at increased risk for meningococcal disease. Access the recommendations at www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm.

Tdap vaccine news

On Feb. 22, CDC published "Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women." The recommendations advise prenatal care providers to administer a dose of Tdap during each pregnancy irrespective of the patient's prior history of receiving Tdap. To obtain the recommendations, go to www.cdc.gov/mmwr/pdf/wk/mm6207.pdf (pages 131–135).

VIS news

On Feb. 27, CDC posted an updated VIS for pneumococcal conjugate vaccine (PCV13). To access the VIS and 13 translations, go to www.immunize.org/vis/vis_pcv.asp.

Starting with the PCV13 VIS, CDC will create supplementary provider information for each new and updated VIS. Intended to help providers answer patient questions, the supplementary document has information about the vaccine, such as contraindications and precautions, as well as links to pertinent ACIP recommendations. Access the PCV13 supplementary document at www.cdc.gov/vaccines/pubs/vis/downloads/vis-pcv-hcp-supplmt.pdf.

On May 9, CDC issued a new VIS for tetanus-diphtheria-acellular pertussis (Tdap) vaccine. It reflects recent changes in ACIP recommendations regarding use of Tdap during pregnancy. **Note:**

"Meningococcal Vaccination Recommendations by Age and/or Risk Factor" [a summary table], at www.immunize.org/catg.d/p2018.pdf.

"Summary of Recommendations for Child/Teen Immunization (Age birth through 18 years)," page 4, at www.immunize.org/catg.d/p2010.pdf.

"Summary of Recommendations for Adult Immunization (Age 19 years & older)," page 4, at www.immunize.org/catg.d/p2011.pdf.

Stay Current!

Subscribe to the
Immunization Action Coalition's
free weekly email immunization
news service, *IAC Express*.

www.immunize.org/subscribe

This VIS contains information about Tdap only; when vaccinating a patient with Td vaccine, providers should give the patient the Td/Tdap VIS (dated 1/24/12) until a VIS dedicated exclusively to Td (currently in development) is available. Access the new Tdap VIS at www.immunize.org/vis/tdap.pdf. Access the provider information for the Tdap VIS at www.cdc.gov/vaccines/pubs/vis/downloads/vis-tdap-hcp.pdf.

For a ready-to-print table of current dates of VISs for posting in your practice, go to www.immunize.org/catg.d/p2029.pdf.

Vaccination error reporting

In December 2012, the Institute for Safe Medication Practices launched its National Vaccine Error Reporting Program (VERP). The program allows healthcare professionals to confidentially report vaccine administration errors and near misses. Its goal is to better quantify sources of errors and advocate for product changes (such as changes to the vaccine name or label) that will ensure patient safety. For additional information and to access an electronic VERP reporting form, go to verp.ismp.org.

Influenza news

On Feb. 27, FDA's Vaccines and Related Biological Products Advisory Committee recommended that trivalent-formulation influenza vaccines for the 2013–14 influenza season contain the following: an A/California/7/2009 (H1N1)-like virus; an (H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011; and a B/Massachusetts/2/2012-like virus. The committee also recommended that the quadrivalent-formulation influenza vaccine contain the previously listed three strains and also a B/Brisbane/60/2008-like virus. For further information, go to www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm343828.htm.

Meningococcal . . . continued from page 1

boosters varies by risk factor. And, finally, products for use in adults age 56 years and older include off-label recommendations. It is important that clinicians access the resources below for specific information on selecting a vaccine product and scheduling vaccination for their patients.

Resources

Prevention and Control of Meningococcal Disease, *MMWR* 2013; 62[No. RR-2], at www.cdc.gov/mmwr/pdf/rr/rr6202.pdf.